Commercialisation agreement for Ocriplasmin

ThromboGenics NV has entered into an agreement with Alcon for the commercialisation of Ocriplasmin in all markets outside the US. As a result of this deal, ThromboGenics will concentrate on commercialising Ocriplasmin in the US where it plans to build its commercial and medical organisation to support the product’s anticipated launch within the next 12 months.
“Under the terms of the agreement with Alcon, ThromboGenics will receive an up-front payment of €75m. The company is also entitled to a further €90m in potential near-term milestone payments. Additional milestones bring the potential total of up-fronts and milestones to €375m,†said a company spokesman. “In addition, ThromboGenics will receive royalties on net sales of Ocriplasmin that are commensurate with a product that has successfully completed Phase III development and that has been filed for regulatory approval,†he said.
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.